Biomarkers for predicting response to aspirin therapy in aspirin‐exacerbated respiratory disease

• DOI: 10.1111/cea.13886
• Publication Date: 2021-04-27T18:38:21Z
• Authors: Katarzyna E. Tyrak; Kinga Pajdzik; Bogdan Jakieła; Izabela Kupryś‐Li...; Adam Ćmiel; Radosław Kacorzyk; Gabriela Trąd; Piotr Kuna; Marek Sanak; Lucyna Mastalerz
• Keywords: Adult; Male; Middle Aged; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Desensitization, Immunologic; Humans; Asthma, Aspirin-Induced; Female; ORIGINAL ARTICLES; Biomarkers

Abstract Background Aspirin desensitization followed by daily aspirin use is an effective treatment for aspirin‐exacerbated respiratory disease (AERD). Objective To assess clinical features as well genetic, immune, cytological and biochemical biomarkers that might predict a positive response to high‐dose therapy in AERD. Methods We enrolled 34 AERD patients with severe asthma who underwent 52‐week (650 mg/d). At baseline at 52 weeks, assessment was performed; phenotypes based on induced sputum cells were identified; eicosanoid, cytokine chemokine levels supernatant determined; expression of 94 genes assessed. Responders defined improvement 5‐item Asthma Control Questionnaire score, 22‐item Sino‐Nasal Outcome Test (SNOT‐22) score forced expiratory volume 1 second weeks. Results There 28 responders (82%). Positive predictors included female sex ( p = .002), higher SNOT‐22 .03), blood eosinophil count .01), lower neutrophil percentage .003), the hydroxyprostaglandin dehydrogenase gene, HPGD .004) proteoglycan 2 PRG2 .01). The best prediction model scores, eosinophils total serum immunoglobulin E. showed marked decrease but no changes eicosanoid levels. Conclusions Clinical Relevance Female sex, high count, low percentage, nasal symptoms, may long‐term